AsclepiX Therapeutics, Inc. — Form D

AsclepiX Therapeutics, Inc. of Bethesda, MD, a company, filed a Form D exempt-offering notice with the SEC on 2018-10-25. The offering totals $7.5M, of which $3.9M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Joshua BarerDirectorRochester, MI
Aleksander Popel, PhDDirectorBaltimore, MD
Kevin Slawin, MDDirectorBaltimore, MD
Steven AltschulerDirectorWATERTOWN, MA
Chris GarabedianDirectorSan Francisco, CA
Robert DempseyExecutive OfficerBethesda, MD
Ben AskewDirectorBethesda, MD
Josh BarerDirectorBethesda, MD
Aleksander PopelExecutive OfficerBethesda, MD
Sapna SrivastavaDirectorBethesda, MD
Amir ShojaeiExecutive OfficerBethesda, MD
Niranjan PandeyExecutive OfficerBethesda, MD
Jill TierneyExecutive OfficerBethesda, MD
Jordan GreenDirectorBethesda, MD
Jordan J GreenDirectorPorte Vedra Beach, FL
Jordan J GreenExecutive OfficerPorte Vedra Beach, FL
Sapna S SrivastavaDirectorBaltimore, MD
Aleksander S Popel, PhDDirectorBaltimore, MD
Aleksander S Popel, PhDExecutive OfficerBaltimore, MD
Kevin S Slawin, MDDirectorBaltimore, MD
Kevin S Slawin, MDExecutive OfficerBaltimore, MD
Steven S Altschuler, MDDirectorBaltimore, MD
Joshua S BarerDirectorBaltimore, MD
Wendy PerrowDirectorBaltimore, MD
Wendy PerrowExecutive OfficerBaltimore, MD

Other filings by this issuer (4)

FiledFormOfferingSold
2024-04-26D$12.5M$10.0M
2020-06-11D$35.0M$10.0M
2019-06-17D/A$10.0M$7.7M
2017-02-09D$1.0M$175K

More